CVE-2025-61940Mirion Medical EC2 Software NMIS BioDose Use of Client-Side Authentication
Updated under an hour ago ()
Does this affect you?
It affects Mirion Medical EC2 Software NMIS BioDose and 1 other product. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
- CVSS
- 8.3 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L
- Weakness (CWE)
- CWE-603
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- icscert
- NVD analysis
- Analyzed
- Record last updated
- Dec 9, 2025
- First seen by InfoSec Signals
- Oct 9, 2026
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.